Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Fluorine 18 THK 5351 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; Pharmacokinetics
- 01 Sep 2017 Results (n=12) assessing biodistribution and radiation dosimetry for the tau tracer 18f-thk-5351 in healthy human subjects, were published in the Journal of Nuclear Medicine.
- 06 Feb 2017 Status changed from recruiting to completed.
- 23 Feb 2016 New trial record